Editas Medicine, Inc. EDIT

Bagholder for very long time

8.31 first target

$EDIT check $FBIO ??

$EDIT ⏰?

Rumours circulating that Editas has received an offer to be acquired at a valuation of $1.5 bn

This stock will be trading at $17-20 in a couple of weeks.

Massively undervalued stock. Average analyst price target is $16, highest is $30. Crazy that it’s trading at such low levels right now.

Stifel analyst Dae Gon Ha upgraded Editas Medicine (NASDAQ: EDIT) from Hold to Buy with a price target of $17.00 (from $9.00).

The analyst comments "We are upgrading EDIT shares to Buy and increasing TP to $17 (vs. $9 previously). We think EDIT-301's (sickle cell disease [SCD]) progress has received minimal credit from investors. But with YE23 goal to dose n=20, in addition to important regulatory insights expected from exa-cel (CRSP, covered by Stifel colleague Ben Burnett), we think EDIT-301 deserves a fresh look. Within, we discuss the disconnect between EDIT and CRSP valuations - at comparable time points in development, EDIT-301's clinical profile thus far (vs. exa-cel), our optimism - both clinically and regulatory - in EDIT-301's strategy (i.e., HBG1/2 promoter region), market receptivity - and TAM - for follow-on gene editing like EDIT-301, and potential upside from the IP dispute.

https://www.streetinsider.com/dr/news.php?id=22214328

$EDIT suck my dick Cathy Wood ?
Bitch, dumb as a bag of rocks ?